| Wang, Liang |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
| Recruiting | 2 | 15 | RoW | Gemcitabine, Pegaspargase, Etoposide, Dexamethasone | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma | 06/21 | 08/21 | | |
NCT04231370: Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab, anti-PD-1-antibody, Lenalidomide, IMids | Beijing Tongren Hospital | NK/T Cell Lymphoma Nos | 02/22 | 12/22 | | |
NCT04279379: Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab, anti-PD-1-antibody, Decitabine, hypomethylating agents | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma | 12/22 | 12/22 | | |
NCT04405375: GPED Regimen for Relapsed/Refractory or Advanced ENKTCL |
|
|
| Recruiting | 2 | 29 | RoW | gemcitabin, Pegaspargase, Etoposide, Dexamethasone | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma, Nasal Type | 04/23 | 04/23 | | |
| Recruiting | 2 | 150 | RoW | Anlotinib Hydrochloride, Placebo, Radiation Therapy, Temozolomide | Sun Yat-sen University | Glioblastoma | 10/23 | 10/23 | | |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
NCT05943691: High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial |
|
|
| Recruiting | 2 | 100 | RoW | hetrombopag 5mg po qd, High-dose Dexamethasone | Shandong University | ITP - Immune Thrombocytopenia | 07/24 | 12/24 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 07/25 | 09/25 | | |
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL |
|
|
| Not yet recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 08/24 | 02/27 | | |
| Not yet recruiting | 2 | 47 | RoW | Golidocitinib, Benmelstobart | Sun Yat-sen University | Natural Killer T-cell Lymphoma | 12/26 | 12/28 | | |
NCT06081478: CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | CD19/CD22-bispecific CAR-T cells | Beijing Tongren Hospital | B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma | 12/25 | 12/26 | | |
NCT06376721: Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 1/2 | 43 | RoW | Linperlisib, YY-20394, Camrelizumab, Camrelizumab for Injection, Pegaspargase, Pegaspargase injection, Dexamethasone, Dexamethasone oral | Beijing Tongren Hospital | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | 10/26 | 10/27 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
| Recruiting | 1/2 | 139 | RoW | LM101, Toripalimab, Rituximab | LaNova Medicines Limited | Malignant Tumors | 01/27 | 01/28 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT06760039: Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL |
|
|
| Not yet recruiting | 1/2 | 112 | RoW | R-CMOP Regimen, R-CHOP Regimen | Sun Yat-sen University | Diffuse Large B-Cell Lymphoma | 08/28 | 11/28 | | |
NCT05532345: Discrimination of DILI and AIH by Artificial Intelligence |
|
|
| Completed | N/A | 2583 | RoW | | Beijing Friendship Hospital | Drug-induced Liver Injury, Autoimmune Hepatitis | 05/23 | 05/23 | | |
NCT06144619: Non-Invasive Biomarkers in Prostate Cancer Disease Management |
|
|
| Recruiting | N/A | 500 | US | Genomic and Histological Evaluation | H. Lee Moffitt Cancer Center and Research Institute | Prostate Cancer | 01/29 | 01/29 | | |
NCT06356506: A Study on Factors of Biochemical Response in Autoimmune Hepatitis |
|
|
| Not yet recruiting | N/A | 630 | RoW | | Beijing Friendship Hospital | Autoimmune Hepatitis | 05/34 | 05/34 | | |
| Recruiting | N/A | 3000 | RoW | | Beijing Friendship Hospital | Drug-induced Liver Injury | 12/26 | 12/28 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
